Abstract
Estramustine phosphate has been used for over 20 years in the treatment of advanced prostate cancer. Recent reports of promising results from clinical combination studies, and neoadjuvant studies, have caused a renewed interest in this relatively old drug. After oral or intravenous administration, estramustine phosphate is metabolised to four main metabolites: estramustine, estromustine, estradiol and estrone. Due to the potential biological activity of all these estramustine phosphate metabolites, it is necessary to analyse the parent compound and all four metabolites in plasma, tissues and tumours. Consequently, various methods have been developed for the bioanalysis of these compounds. In this review various methods are described for the analysis of estramustine phosphate and its metabolites in biological fluids and tissues. Methods described included RIA, TLC, HPLC, HPLC-MS, GC and GC-MS.
Keywords: nor-nitrogen mustard conjugate, prostate cancer, plasma clearance, bioavailability, high first-pass metabolism, non-chromatographic assay procedure, estradiol, chromatography, spectrometry, estrone
Current Pharmaceutical Analysis
Title: A Short Review of Analytical Methods for the Determination of Estramustine Phosphate and its Metabolites in Biological Samples
Volume: 1 Issue: 2
Author(s): Massimo Breda and Christopher A. James
Affiliation:
Keywords: nor-nitrogen mustard conjugate, prostate cancer, plasma clearance, bioavailability, high first-pass metabolism, non-chromatographic assay procedure, estradiol, chromatography, spectrometry, estrone
Abstract: Estramustine phosphate has been used for over 20 years in the treatment of advanced prostate cancer. Recent reports of promising results from clinical combination studies, and neoadjuvant studies, have caused a renewed interest in this relatively old drug. After oral or intravenous administration, estramustine phosphate is metabolised to four main metabolites: estramustine, estromustine, estradiol and estrone. Due to the potential biological activity of all these estramustine phosphate metabolites, it is necessary to analyse the parent compound and all four metabolites in plasma, tissues and tumours. Consequently, various methods have been developed for the bioanalysis of these compounds. In this review various methods are described for the analysis of estramustine phosphate and its metabolites in biological fluids and tissues. Methods described included RIA, TLC, HPLC, HPLC-MS, GC and GC-MS.
Export Options
About this article
Cite this article as:
Breda Massimo and James A. Christopher, A Short Review of Analytical Methods for the Determination of Estramustine Phosphate and its Metabolites in Biological Samples, Current Pharmaceutical Analysis 2005; 1 (2) . https://dx.doi.org/10.2174/1573412054022716
DOI https://dx.doi.org/10.2174/1573412054022716 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents
Current Drug Targets New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone
Anti-Cancer Agents in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Current Cancer Drug Targets